asthma intervention cost effective for us inner-city children
Post on 23-Dec-2016
214 views
TRANSCRIPT
PharmacoEconomics & Outcomes News 392 - 7 Dec 2002
Asthma intervention cost effectivefor US inner-city children
A multifaceted, social worker-based intervention forinner-city children with asthma is cost effective in theUS, and is cost saving among those with severe disease,report researchers from that country.
They prospectively assessed direct costs andoutcomes among 1033 children with asthma (aged 5–11years) who were enrolled in the multicentre NationalCooperative Inner-City Asthma Study, over a 2-yearperiod.* Children were randomised to a 12-monthfamily programme with environmental control andtrained social workers as asthma counsellors, or to usualcare. The mean number of asthma symptom-free daysimproved significantly for the intervention, comparedwith the usual care, group, over the 2-year period (565.1vs 538.5 days) at an additional cost of $US245 perchild;** no statistically significant differences wereobserved in the use of medical care. Compared withusual care, the incremental cost effectiveness ratio of theintervention was $US9.20 per symptom-free daygained.
Sensitivity analyses revealed the results to be sensitiveto the mean cost associated with the intervention, whichwould have to be less than $US92 per child to be costsaving, on average. ‘Importantly, in the subgroups ofchildren with more severe asthma, the intervention wassubstantially more effective and reduced the total cost ofmedical care’, the researchers note.* The study was supported in part by a research grant fromGlaxoSmithKline.** Costs (1995 values) were those related to the intervention,hospitalisation, emergency-department and clinic visits, and asthma-control devices, and were calculated from a Medicaid payerperspective. Costs and benefits were discounted at 3% during thesecond year.
Sullivan SD, et al. The cost-effectiveness of an inner-city asthma intervention forchildren. Journal of Allergy and Clinical Immunology 110: 576-581, Oct2002 800926148
1
PharmacoEconomics & Outcomes News 7 Dec 2002 No. 3921173-5503/10/0392-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved